T1	Participants 68 101	patients with early breast cancer
T2	Participants 260 287	premenopausal breast cancer
T3	Participants 345 385	285 premenopausal breast cancer patients
T4	Participants 964 979	goserelin group
T5	Participants 1034 1049	tamoxifen group
T6	Participants 1062 1077	tamoxifen group
T7	Participants 1109 1137	women treated with goserelin
T8	Participants 1494 1511	CMF treated women
